{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:24:37Z","timestamp":1776090277261,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.eururo.2003.09.014","type":"journal-article","created":{"date-parts":[[2003,10,15]],"date-time":"2003-10-15T19:18:58Z","timestamp":1066245538000},"page":"182-186","source":"Crossref","is-referenced-by-count":40,"title":["Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study"],"prefix":"10.1016","volume":"45","author":[{"given":"J.A.","family":"Witjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.J.","family":"Vriesema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Laan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Schalken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2003.09.014_BIB1","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","article-title":"A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J. Urol."},{"issue":"2\u20133","key":"10.1016\/j.eururo.2003.09.014_BIB3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/02841860151116466","article-title":"A Systematic Overview of Chemotherapy Effects in Urothelial Bladder Cancer","volume":"40","author":"Nilsson","year":"2001","journal-title":"Acta Oncol."},{"issue":"7","key":"10.1016\/j.eururo.2003.09.014_BIB4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB5","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","article-title":"A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer","volume":"156","author":"Pawinski","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","article-title":"Long-term results of intravesical therapy for superficial bladder cancer","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.eururo.2003.09.014_BIB7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","article-title":"Bacillus Calmette Guerin and superficial transitional cell carcinoma","volume":"82","author":"Mungan","year":"1998","journal-title":"Brit. J. Urol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1368-7646(02)00002-X","article-title":"Determinants of resistance to 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine)","volume":"5","author":"Bergman","year":"2002","journal-title":"Drug Res. Updates"},{"key":"10.1016\/j.eururo.2003.09.014_BIB10","first-page":"2629","article-title":"Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs","volume":"5","author":"Cozzi","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.eururo.2003.09.014_BIB11","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.1999.17.7.2190","article-title":"Gemcitabine and paclitaxel pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer","volume":"17","author":"Kroep","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/oxfordjournals.annonc.a058775","article-title":"Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase 1 study","volume":"5","author":"Pollera","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB15","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.eururo.2003.09.014_BIB17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000055202","article-title":"Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma\u2014prognostic factors for response and improvement of quality of life","volume":"25","author":"Albers","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/j.eururo.2003.09.014_BIB18","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.1999.17.9.2876","article-title":"Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"17","author":"Moore","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000012132","article-title":"Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function","volume":"59","author":"Carles","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.eururo.2003.09.014_BIB20","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","article-title":"Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer","volume":"19","author":"Hussain","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB21","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","article-title":"Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network","volume":"19","author":"Meluch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB22","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2","article-title":"Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy","volume":"92","author":"Sternberg","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2003.09.014_BIB23","first-page":"1229","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"19","author":"von der Maase","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","article-title":"Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of an European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillations of thiotepa, doxorubicin and cisplatin","volume":"148","author":"Bouffioux","year":"1992","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.014_BIB25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(19820901)50:5<863::AID-CNCR2820500509>3.0.CO;2-Q","article-title":"Intravesical cisplatin for superficial bladder tumors","volume":"50","author":"Blumenreich","year":"1982","journal-title":"Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803004822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803004822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T02:06:24Z","timestamp":1623463584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283803004822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0302283803004822"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2003.09.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}